Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This trial evaluated the safety and efficacy of ipatasertib in combination with different chemotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and the overall response rates and progression-free survival varied among the different treatment arms. Further study is needed to better understand the role of AKT inhibition in the treatment of TNBCs.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This study evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoints were safety and recommended phase II dose (RP2D), while secondary endpoints included progression-free survival (PFS), response rate, and overall survival. The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and further research is needed to understand the role of AKT inhibition in the treatment of TNBC.
Article
Oncology
Julia Foldi, Andrea Silber, Emily Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michal Marczyk, Courtney Frederick, Trisha Burrello, Eiman Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L. Rimm, Lajos Pusztai
Summary: The Phase I/II trial aimed to evaluate the safety and efficacy of durvalumab in combination with other therapies for triple-negative breast cancer. The study found that the combination treatment resulted in a 44% pathologic complete response rate, with some patients experiencing grade 3/4 adverse events. Results suggest potential benefits of the combination therapy, particularly in patients with high stromal tumor-infiltrating lymphocytes.
Article
Oncology
Yuan Yuan, Jin Sun Lee, Susan E. Yost, Sierra Min Li, Paul H. Frankel, Christopher Ruel, Daniel Schmolze, Kim Robinson, Aileen Tang, Norma Martinez, Daphne Stewart, James Waisman, Laura Kruper, Veronica Jones, Andrea Menicucci, Sahra Uygun, Erin Yoder, Bastiaan van der Baan, John H. Yim, Christina Yeon, George Somlo, Joanne Mortimer
Summary: The combination of carboplatin and nab-paclitaxel showed manageable toxicity and encouraging antitumor activity in early stage high-risk triple-negative breast cancer. Immune-hot GSIS was associated with higher pCR rate and RCB class 0/1, providing rationale for future neoadjuvant trials in TNBC. Additional development of GSIS as a clinically applicable assay is indicated.
Article
Oncology
Rebecca Dent, Mafalda Oliveira, Steven J. Isakoff, Seock-Ah Im, Marc Espie, Sibel Blau, Antoinette R. Tan, Cristina Saura, Matthew J. Wongchenko, Na Xu, Denise Bradley, Sarah-Jayne Reilly, Aruna Mani, Sung-Bae Kim
Summary: In a study on triple-negative breast cancer patients, adding the oral AKT inhibitor ipatasertib to paclitaxel treatment prolonged overall survival, especially in patients with specific gene alterations. The final overall survival results showed a numerical trend favoring the ipatasertib-paclitaxel group, with a median survival exceeding 2 years.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Cell Biology
Chifei Kang, Ran Rostoker, Sarit Ben-Shumel, Rola Rashed, James Andrew Duty, Deniz Demircioglu, Irini M. Antoniou, Lika Isakov, Zila Shen-Orr, Jose Javier Bravo-Cordero, Nathan Kase, Math P. Cuajungco, Thomas M. Moran, Derek LeRoith, Emily Jane Gallagher
Summary: TMEM176B plays a crucial role in regulating key signaling pathways and genes in breast cancer cells, affecting cancer cell growth and progression. It is a potential target for therapeutic antibodies to inhibit tumor growth.
Article
Engineering, Biomedical
Beibei Guo, Yan Qu, Yinping Sun, Songsong Zhao, Jiandong Yuan, Peizhuo Zhang, Zhiyuan Zhong, Fenghua Meng
Summary: The combination of integrin-targeting micellar gemcitabine and paclitaxel (ATN-mG/P) with polymersomal CpG (NanoCpG) effectively heats up and treats TNBC, promoting anti-cancer immune responses.
BIOACTIVE MATERIALS
(2023)
Article
Biochemistry & Molecular Biology
Hatem Soliman, Deanna Hogue, Hyo Han, Blaise Mooney, Ricardo Costa, Marie C. Lee, Bethany Niell, Angela Williams, Alec Chau, Shannon Falcon, Aixa Soyano, Avan Armaghani, Nazanin Khakpour, Robert J. Weinfurtner, Susan Hoover, John Kiluk, Christine Laronga, Marilin Rosa, Hung Khong, Brian Czerniecki
Summary: This article presents the phase 2 trial of T-VEC plus NAC for triple-negative breast cancer (TNBC). The study found that T-VEC plus NAC may increase RCB0-1 rates in TNBC patients, supporting further investigation of this treatment approach.
Article
Biochemistry & Molecular Biology
Yan Chang, Hui-Qin Jia, Bin Xu, Liu Yang, Ye-Tong Xu, Jing-Yu Zhang, Mei-Qi Wang, Li-Xian Yang, Zhen-Chuan Song
Summary: This study demonstrates that MTDH inhibits chemosensitivity of TNBC to PTX by activating the AKT/GSK-3β signaling pathway. Higher expression of MTDH or AKT is associated with poorer disease-free survival and lower Miller-Payne grade. Suppression of AKT terminates MTDH-induced cell proliferation and apoptosis, and increases chemosensitivity to PTX.
CHEMICAL BIOLOGY & DRUG DESIGN
(2023)
Article
Cell & Tissue Engineering
Sidse Ehnnsen, Henrik J. Ditzel
Summary: Breast cancer stem cells play a crucial role in cancer initiation, therapy resistance, and progression, with recent research focusing on cellular signaling pathways such as the WNT pathway, NF-κB pathway, and cholesterol biosynthesis pathway. Targeting these pathways in combination with standard treatments may improve the prognosis of breast cancer patients.
Article
Cell Biology
Fengzhu Guo, Jialu Ma, Cong Li, Shuning Liu, Weizheng Wu, Chunxiao Li, Jiani Wang, Jinsong Wang, Zhijun Li, Jingtong Zhai, Fangzhou Sun, Yantong Zhou, Changyuan Guo, Haili Qian, Binghe Xu
Summary: This study investigated the role of PRR15 in triple-negative breast cancer (TNBC) and its clinical applications. The expression of PRR15 was found to be different between TNBC and non-TNBC patients, and its down-regulation promoted malignant progression in TNBC through the PI3K/Akt signaling pathway. Decreased PRR15 expression in TNBC was associated with more aggressive clinicopathological characteristics, enhanced metastasis, and poor disease-free survival. These findings suggest that PRR15 could serve as a promising indicator of disease outcomes in TNBC.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Lu Yang, Shaorong Zhao, Tong Zhu, Jin Zhang
Summary: This study identified GPRC5A as a protective factor against the progression of human triple-negative breast cancer by increasing cell apoptosis via the regulation of the PI3K/Akt signaling pathway. The results suggest that GPRC5A could be a potential therapeutic target for breast cancer treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Frederik Marme, Christine Solbach, Laura Michel, Andreas Schneeweiss, Jens-Uwe Blohmer, Jens Huober, Peter A. Fasching, Christian Jackisch, Valentina Nekljudova, Theresa Link, Kerstin Rhiem, Julia Rey, Carsten Denkert, Claus Hanusch, Hans Tesch, Bianca Lederer, Sibylle Loibl, Michael Untch
Summary: In triple negative breast cancer, pathological complete response is associated with superior survival. The CPS + EG system provides refined estimate of prognosis but is less superior compared to pathological stage. Pathological complete response remains the strongest and most clinically useful prognostic factor after neoadjuvant chemotherapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Jesse Lopes da Silva, Lucas Zanetti de Albuquerque, Fabiana Resende Rodrigues, Guilherme Gomes de Mesquita, Priscila Valverde Fernandes, Luiz Claudio Santos Thuler, Andreia Cristina de Melo
Summary: This study found that the immune cell subtype in the tumor microenvironment after neoadjuvant chemotherapy can be a determining factor in the prognosis of patients with triple-negative breast cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
J. Cortes, H. S. Rugo, D. W. Cescon, S-A Im, M. M. Yusof, C. Gallardo, O. Lipatov, C. H. Barrios, J. Perez-Garcia, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Z. Guo, X. Zhou, V Karantza, W. Pan, P. Schmid
Summary: The addition of pembrolizumab to chemotherapy significantly improves overall survival in patients with advanced triple-negative breast cancer whose tumors express PD-L1 with a CPS of 10 or more.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Oncology
Andri Papakonstantinou, Nadia Saoudi Gonzalez, Isabel Pimentel, Anna Sunol, Esther Zamora, Carolina Ortiz, Martin Espinosa-Bravo, Vicente Peg, Ana Vivancos, Cristina Saura, Guillermo Villacampa, Mafalda Oliveira
Summary: Circulating tumor DNA (ctDNA) is a prognostic marker in patients with early breast cancer (EBC) treated with neoadjuvant therapy (NAT), with significant associations to worse relapse-free survival (RFS) and overall survival (OS).
CANCER TREATMENT REVIEWS
(2022)
Article
Oncology
Andrew B. Lassman, Juan Manuel Sepulveda-Sanchez, Timothy F. Cloughesy, Miguel J. Gil-Gil, Vinay K. Puduvalli, Jeffrey J. Raizer, Filip Y. F. De Vos, Patrick Y. Wen, Nicholas A. Butowski, Paul M. J. Clement, Morris D. Groves, Cristobal Belda-Iniesta, Pierre Giglio, Harris S. Soifer, Steven Rowsey, Cindy Xu, Francesca Avogadri, Ge Wei, Susan Moran, Patrick Roth
Summary: The selective FGFR1-3 inhibitor infigratinib showed limited efficacy in patients with FGFR-altered recurrent gliomas, but it may provide durable disease control in patients with tumors harboring FGFR1 or FGFR3 point mutations or FGFR3-TACC3 fusions.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Joan Albanell, Jose Manuel Perez-Garcia, Miguel Gil-Gil, Giuseppe Curigliano, Manuel Ruiz-Borrego, Laura Comerma, Joan Gibert, Meritxell Bellet, Begona Bermejo, Lourdes Calvo, Juan de la Haba, Enrique Espinosa, Alessandro Marco Minisini, Vanesa Quiroga, Ana Santaballa Bertran, Leonardo Mina, Beatriz Bellosillo, Federico Rojo, Silvia Menendez, Miguel Sampayo-Cordero, Crina Popa, Andrea Malfettone, Javier Cortes, Antonio Llombart-Cussac
Summary: This study assessed the efficacy and biomarkers of continuing palbociclib plus endocrine therapy in patients with advanced breast cancer who had progression on prior palbociclib-based regimen. The results suggest that maintaining palbociclib after progression may be a reasonable approach for selected patients, and a biomarker signature predicts a subset of patients who may not derive greater benefit from palbociclib rechallenge.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Sibylle Loibl, Delphine Loirat, Sara M. Tolaney, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Aditya Bardia, Sara A. Hurvitz, Adam M. Brufsky, Kevin Kalinsky, Javier Cortes, Joyce A. O'Shaughnessy, Veronique Dieras, Lisa A. Carey, Luca Gianni, Mahdi Gharaibeh, Luciana Preger, See Phan, Lawrence Chang, Ling Shi, Martine J. Piccart
Summary: This study investigated the effect of the antibody-drug conjugate sacituzumab govitecan (SG) on the health-related quality of life (HRQoL) in patients with metastatic triple-negative breast cancer (mTNBC). The results showed that SG was associated with greater improvements and delayed worsening of HRQoL scores compared with other treatment options chosen by physicians.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Braso-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Odena, Monica Sanchez-Guixe, Marta Capelan, Analia Azaro, Alejandra Bruna, Olga Rodriguez, Marta Guzman, Judit Grueso, Cristina Viaplana, Javier Hernandez, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquin Arribas, Stefan Michiels, Alicia Garcia-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Summary: CDK4/6 inhibitors combined with endocrine therapy show higher antitumor activity in the treatment of estrogen receptor-positive breast cancer. Overexpression of p16 is associated with reduced effectiveness of CDK4/6 inhibitors, while heterozygous RB1 loss is a biomarker of acquired resistance and poor clinical outcome. Combination of CDK4/6 inhibitor ribociclib with PI3K inhibitor alpelisib demonstrates antitumor activity regardless of specific mutations, even without endocrine therapy.
NATURE COMMUNICATIONS
(2022)
Review
Oncology
Andri Papakonstantinou, Paolo Nuciforo, Maria Borrell, Esther Zamora, Isabel Pimentel, Cristina Saura, Mafalda Oliveira
Summary: The microbial composition of breast tissue and tumors differs from normal breast tissue and other tumor types, potentially correlating with breast cancer subtype and stage. The interaction between gut and breast microbiomes and the relationship between gut microbiome and breast cancer therapy are still not well understood.
CANCER TREATMENT REVIEWS
(2022)
Correction
Multidisciplinary Sciences
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Braso-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Odena, Monica Sanchez-Guixe, Marta Capelan, Analia Azaro, Alejandra Bruna, Olga Rodriguez, Marta Guzman, Judit Grueso, Cristina Viaplana, Javier Hernandez, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquin Arribas, Stefan Michiels, Alicia Garcia-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Nancy U. Lin, Rashmi K. Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot, Philippe L. Bedard, Virginia Borges, David Cameron, Lisa A. Carey, A. Jo Chien, Giuseppe Curigliano, Michael P. DiGiovanna, Karen Gelmon, Gabriel Hortobagyi, Sara A. Hurvitz, Ian Krop, Sherene Loi, Sibylle Loibl, Volkmar Mueller, Mafalda Oliveira, Elisavet Paplomata, Mark Pegram, Dennis Slamon, Amelia Zelnak, Jorge Ramos, Wentao Feng, Eric Winer
Summary: This study evaluated the efficacy of tucatinib in combination with trastuzumab and capecitabine in patients with ERBB2-positive MBC and BMs. The results showed that this treatment option improved overall survival and reduced the risk of developing new brain lesions, indicating its importance for these patients.
Article
Oncology
M. Oliveira, C. Falato, J. M. Cejalvo, M. Margeli Vila, P. Tolosa, F. J. Salvador-Bo, J. Cruz, M. Arumi, A. M. Luna, J. A. Guerra, M. Vidal, O. Martinez-Saez, L. Pare, B. Gonzalez-Farre, E. Sanfeliu, E. Ciruelos, M. Espinosa-Bravo, S. Pernas, Y. Izarzugaza, S. Esker, P. -D Fan, P. Parul, A. Santhanagopal, D. Sellami, G. Villacampa, J. M. Ferrero-Cafiero, T. Pascual, A. Prat
Summary: This study aimed to evaluate the biological and clinical activity of HER3-DXd in patients with early breast cancer. The results showed that a single dose of HER3-DXd could increase immune infiltration, suppress proliferation, and had a good safety profile. Therefore, further research on HER3-DXd in early breast cancer treatment is warranted.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Angel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Munoz-Mateu, Begon Bermejo, Mireia Margeli Vila, Antonio Anton, Laura Murillo, Bella Nissenbaum, Yuan Liu, Jesus Herranz, Daniel Fernandez-Garcia, Rosalia Caballero, Jose Antonio Lopez-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas Turner, Miguel Martin
Summary: In patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer, non-luminal subtype and high CCNE1 expression are associated with resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and poor response to treatment. Furthermore, high levels of the Polo-like kinase 1 (PLK1) mRNA indicate resistance to palbociclib, suggesting that PLK1 may play a role in CDK4/6i resistance. These findings highlight the need for validation of these biomarkers and the exploration of PLK1 as a therapeutic target.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortes, Henry L. Gomez Moreno, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo
Summary: Capivasertib-fulvestrant therapy significantly improves progression-free survival in patients with hormone receptor-positive advanced breast cancer, particularly those with AKT pathway alterations.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Multidisciplinary Sciences
Aleix Prat, Fara Braso-Maristany, Olga Martinez-Saez, Esther Sanfeliu, Youli Xia, Meritxell Bellet, Patricia Galvan, Debora Martinez, Tomas Pascual, Mercedes Marin-Aguilera, Anna Rodriguez, Nuria Chic, Barbara Adamo, Laia Pare, Maria Vidal, Mireia Margeli, Ester Ballana, Marina Gomez-Rey, Mafalda Oliveira, Eudald Felip, Judit Matito, Rodrigo Sanchez-Bayona, Anna Sunol, Cristina Saura, Eva Ciruelos, Pablo Tolosa, Montserrat Munoz, Blanca Gonzalez-Farre, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Ana Vivancos
Summary: This study uses shallow WGS to create machine learning signatures to identify tumor phenotypes and predict therapy response in metastatic breast cancer patients. Machine learning multi-gene signatures obtained from ctDNA can identify complex biological features similar to those obtained from direct tumor tissue DNA or RNA profiling.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Hector Perez-Montero, Alicia Lozano, Rodolfo de Blas, Juan Jose Sanchez, Evelyn Martinez, Maria Laplana, Miguel Gil-Gil, Amparo Garcia-Tejedor, Sonia Pernas, Catalina Falo, Oscar Godino, Maria J. Pla, Ferran Guedea, Arturo Navarro-Martin
Summary: This study reports a 10-year experience of bone stereotactic body radiation therapy (SBRT) in patients with breast cancer (BC) and bone metastases, analyzing toxicity and prognostic factors. The results show that SBRT is a safe and effective technique for BC, and it should be considered after prior systemic treatment.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Salvador Blanch, Juan Miguel Gil-Gil, Miriam Arumi, Elena Aguirre, Miguel Angel Segui, Manuel Atienza, Silvia Diaz-Cerezo, Alberto Molero, Jose Manuel Cervera, Joaquin Gavila
Summary: This retrospective study in Spain found that abemaciclib is effective for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. It can be used as monotherapy or in combination with endocrine therapy.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)